Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165692 | 0.87 | ADAMTS5 (0.60) | KMT2ASMN1; SMN2PKMNPC1RAB9A | |
| SCHEMBL4244645 | 0.85 | KMT2A (0.62) | EPHX2KMT2ASMN1; SMN2CYP2C9CYP2J2 | |
| SCHEMBL4244552 | 0.83 | PARP10 (0.57) | EPHX2CYP2C9CYP2J2NPC1RAB9A | |
| SCHEMBL4246343 | 0.82 | MEN1 (0.55) | KMT2ASMN1; SMN2 | |
| SCHEMBL4251982 | 0.81 | DGAT1 (0.54) | KMT2ASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4240704 | 0.81 | EPHX2 (0.55) | EPHX2KMT2ACYP2C9CYP2J2 | |
| SCHEMBL12509353 | 0.80 | FAAH (0.67) | KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2193063 | 0.80 | MAPT (0.63) | EPHX2KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19610351 | 0.79 | FAAH (0.52) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL4244661 | 0.78 | KMT2A (0.59) | EPHX2KMT2ASMN1; SMN2CYP2C9CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | EPHX2 1860/4885KMT2A 3249/4885SMN1; SMN2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.